These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy. Chung C Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103 [TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors in multiple myeloma: A review of the literature. Caserta S; Innao V; Musolino C; Allegra A Pathol Res Pract; 2020 Oct; 216(10):153114. PubMed ID: 32853951 [TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint blockade in hematologic malignancies. Armand P Blood; 2015 May; 125(22):3393-400. PubMed ID: 25833961 [TBL] [Abstract][Full Text] [Related]
6. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma. Podar K; Jager D Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of Lymphoma and Myeloma: Facts and Hopes. Pianko MJ; Moskowitz AJ; Lesokhin AM Clin Cancer Res; 2018 Mar; 24(5):1002-1010. PubMed ID: 28899972 [TBL] [Abstract][Full Text] [Related]
8. Novel Immunotherapies for Multiple Myeloma. D'Agostino M; Boccadoro M; Smith EL Curr Hematol Malig Rep; 2017 Aug; 12(4):344-357. PubMed ID: 28819882 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for the treatment of multiple myeloma. Jung SH; Lee HJ; Vo MC; Kim HJ; Lee JJ Crit Rev Oncol Hematol; 2017 Mar; 111():87-93. PubMed ID: 28259300 [TBL] [Abstract][Full Text] [Related]
11. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells. Kim N; Kim HS Front Immunol; 2018; 9():2041. PubMed ID: 30250471 [TBL] [Abstract][Full Text] [Related]
13. The challenges of checkpoint inhibition in the treatment of multiple myeloma. Paul B; Kang S; Zheng Z; Kang Y Cell Immunol; 2018 Dec; 334():87-98. PubMed ID: 30342750 [TBL] [Abstract][Full Text] [Related]
14. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
15. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730 [TBL] [Abstract][Full Text] [Related]
16. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors. Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):471-478. PubMed ID: 28689001 [TBL] [Abstract][Full Text] [Related]
17. Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon? Chocarro de Erauso L; Zuazo M; Arasanz H; Bocanegra A; Hernandez C; Fernandez G; Garcia-Granda MJ; Blanco E; Vera R; Kochan G; Escors D Front Pharmacol; 2020; 11():441. PubMed ID: 32317979 [TBL] [Abstract][Full Text] [Related]
18. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Xia L; Liu Y; Wang Y Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829 [TBL] [Abstract][Full Text] [Related]
19. Immune-Checkpoint Blockade Therapy in Lymphoma. Kuzume A; Chi S; Yamauchi N; Minami Y Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751706 [TBL] [Abstract][Full Text] [Related]
20. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors? Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]